MicroRNA‐26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin‐6‐Stat3 pathway

Down‐regulation of microRNA‐26a (miR‐26a) is associated with poor prognosis of hepatocellular carcinoma (HCC), but its functional mechanism in HCC remains unclear. In this study, we investigated the roles of miR‐26a in tumor growth and metastasis of HCC and found that miR‐26a was frequently down‐regulated in HCC tissues. Down‐regulation of miR‐26a correlated with HCC recurrence and metastasis. Through gain‐ and loss‐of‐function studies, miR‐26a was demonstrated to significantly inhibit in vitro cell proliferation, migration, and invasion. In addition, miR‐26a induced G1 arrest and promoted apoptosis of HCC cells. Importantly, miR‐26a suppressed in vivo tumor growth and metastasis in nude mice models bearing human HCC. Interleukin‐6 (IL‐6) was identified as a target of miR‐26a. Knockdown of IL‐6 induced effects on HCC cells similar to those induced by miR‐26a. In contrast, IL‐6 treatment abrogated the effects induced by miR‐26a up‐regulation. Moreover, miR‐26a dramatically suppressed expression of signal transducer and activator of transcription 3 (Stat3) target genes, including Bcl‐2, Mcl‐1, cyclin D1, and MMP2. IL‐6 treatment antagonized this effect, while knockdown of IL‐6 by IL‐6 short hairpin RNA (shIL‐6) induced inhibitory effects on the expression of p‐Stat3 and its main target genes, similar to miR‐26a. The messenger RNA and protein levels of IL‐6 inversely correlated with miR‐26a in HCCs. Patients with high miR‐26a or low IL‐6 in HCC tissues had a better prognosis with longer overall survival (OS) and time to recurrence (TTR). In multivariate analysis, miR‐26a, IL‐6, and their combination were demonstrated to be independent prognostic indicators for OS and TTR of HCC patients. Conclusion: miR‐26a could suppress tumor growth and metastasis of HCC through IL‐6‐Stat3 signaling and is a novel prognostic marker and therapeutic target for HCC. (HEPATOLOGY 2013)

[1]  Changli Wang,et al.  MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. , 2012, Biochimica et biophysica acta.

[2]  Tong Wu,et al.  MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin. , 2012, Gastroenterology.

[3]  Dong-ping Wang,et al.  Down-Regulation of microRNA-26a Promotes Mouse Hepatocyte Proliferation during Liver Regeneration , 2012, PloS one.

[4]  Jian-Rong Yang,et al.  MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein , 2011, Nucleic acids research.

[5]  Jing Ping Zhang,et al.  MicroRNA‐29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression , 2011, Hepatology.

[6]  D. Cui,et al.  Tumor-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Bo Zhang,et al.  Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. , 2011, Carcinogenesis.

[8]  Lu Wang,et al.  MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. , 2011, Cancer research.

[9]  Yan Liu,et al.  Inhibition of STAT3 Signaling Blocks the Anti-apoptotic Activity of IL-6 in Human Liver Cancer Cells* , 2010, The Journal of Biological Chemistry.

[10]  Z. Culig,et al.  Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells , 2010, Endocrine-related cancer.

[11]  Wei Huang,et al.  Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship , 2010, Proceedings of the National Academy of Sciences.

[12]  J. Yun,et al.  Effects of MicroRNA‐29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma , 2009, Hepatology.

[13]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[14]  Stephanie Roessler,et al.  MicroRNA expression, survival, and response to interferon in liver cancer. , 2009, The New England journal of medicine.

[15]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[16]  Kathryn A. O’Donnell,et al.  Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.

[17]  Reuven Agami,et al.  The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. , 2009, Genes & development.

[18]  Jian-Rong Yang,et al.  MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. , 2009, Cancer research.

[19]  A. Donfrancesco,et al.  Deregulated expression of miR-26a and Ezh2 in Rhabdomyosarcoma , 2009, Cell cycle.

[20]  Dietmar Fuchs,et al.  Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. , 2008, Endocrine-related cancer.

[21]  J. Pollack,et al.  MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. , 2008, Blood.

[22]  C. Croce,et al.  MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma , 2008, Oncogene.

[23]  Krista A. Zanetti,et al.  Identification of metastasis‐related microRNAs in hepatocellular carcinoma , 2008, Hepatology.

[24]  S. Fan,et al.  Significance of CD90+ cancer stem cells in human liver cancer. , 2008, Cancer cell.

[25]  M. Brandi,et al.  Osteogenic Differentiation of Human Adipose Tissue‐Derived Stem Cells Is Modulated by the miR‐26a Targeting of the SMAD1 Transcription Factor , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  Tsung-Cheng Chang,et al.  Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.

[27]  C. Croce,et al.  Specific microRNAs are downregulated in human thyroid anaplastic carcinomas , 2007, Oncogene.

[28]  Q. Ye,et al.  Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. , 2007, Journal of hepatology.

[29]  Michael Karin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .

[30]  Zhao-You Tang,et al.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Segal,et al.  Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. , 2007, Anticancer research.

[32]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[33]  K. Tsuneyama,et al.  Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. , 2006, Anticancer research.

[34]  K. Aldape,et al.  Activation of stat3 in human melanoma promotes brain metastasis. , 2006, Cancer research.

[35]  M. Peck-Radosavljevic,et al.  Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. , 2006, Journal of hepatology.

[36]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[37]  Chang-Zheng Chen,et al.  MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.

[38]  Haiyang Xie,et al.  Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2. , 2005, World journal of gastroenterology.

[39]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[40]  F. Ali-Osman,et al.  Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis , 2004, Oncogene.

[41]  D. Tweardy,et al.  Interleukin‐6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway , 2000, The Prostate.

[42]  N. Nishida,et al.  Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. , 1994, Cancer research.

[43]  R. Kerbel,et al.  Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression [published erratum appears in J Cell Biol 1993 Apr;121(2):following 477] , 1993, The Journal of cell biology.